How Should HR+/HER2- Metastatic Breast Cancer Be Sequenced Today?

In this clip, Prof. Giuseppe Curigliano reviews the evolving treatment landscape in HR-positive, HER2-negative metastatic breast cancer, with a focus on resistance biology, biomarker-guided therapy, oral SERDs, PI3K/AKT-pathway targeting, PARP inhibitors, and ADC sequencing. The presenting expert is Prof. Giuseppe Curigliano, a leading breast cancer specialist with a strong focus on precision oncology, novel therapies, and biomarker-driven treatment strategies in breast cancer. Key highlights from this clip: ●How treatment sequencing may differ between endocrine-sensitive and endocrine-resistant HR+/HER2- metastatic breast cancer ●Why PIK3CA, ESR1, AKT, PTEN, and BRCA testing is becoming increasingly important in clinical decision-making ●What recent studies suggest about inavolisib-based triplet therapy in PIK3CA-mutant disease ●How liquid biopsy and ESR1 monitoring may help identify resistance before radiologic progression ●Where oral SERDs and SERD-based combinations may fit after prior endocrine therapy and CDK4/6 inhibition ●How ADCs such as trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan may be incorporated across later-line settings This video is intended for medical education and professional discussion. #medj #breastcancer #metastaticbreastcancer #HRPositiveBreastCancer #HER2Negative #PIK3CA #ESR1 #CDK46 #OralSERD #precisionmedicine #ADC #TrastuzumabDeruxtecan #SacituzumabGovitecan #medicaloncology